{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:40:33Z","timestamp":1792928433626,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mathematical Biosciences"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.mbs.2022.108954","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T12:05:16Z","timestamp":1670933116000},"page":"108954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Towards a new combination therapy with vectored immunoprophylaxis for HIV: Modeling \u201cshock and kill\u201d strategy"],"prefix":"10.1016","volume":"355","author":[{"given":"Qi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-5627","authenticated-orcid":false,"given":"Yuming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.mbs.2022.108954_b1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella\u00a0Jr.","year":"1998","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.mbs.2022.108954_b2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","article-title":"Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy","volume":"5","author":"Finzi","year":"1999","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.mbs.2022.108954_b3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/infdis\/jiv218","article-title":"Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies","volume":"212","author":"Crooks","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.mbs.2022.108954_b4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.mbs.2022.108954_b5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jtbi.2009.06.011","article-title":"Modeling HIV persistence, the latent reservoir, and viral blips","volume":"260","author":"Rong","year":"2009","journal-title":"J. Theoret. Biol."},{"issue":"6756","key":"10.1016\/j.mbs.2022.108954_b6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/44755","article-title":"Re-emergence of HIV after stopping therapy","volume":"401","author":"Chun","year":"1999","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.mbs.2022.108954_b7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005000","article-title":"HIV reactivation from latency after treatment interruption occurs on average every 5-8 days\u2014implications for HIV remission","volume":"11","author":"Pinkevych","year":"2015","journal-title":"PLoS Pathog."},{"issue":"7408","key":"10.1016\/j.mbs.2022.108954_b8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"Shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.mbs.2022.108954_b9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2019.03.008","article-title":"HIV \u201cshock and kill\u201d therapy: In need of revision","volume":"166","author":"Abner","year":"2019","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.mbs.2022.108954_b10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.it.2016.12.003","article-title":"HIV latency: should we shock or lock?","volume":"38","author":"Darcis","year":"2017","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.mbs.2022.108954_b11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004071","article-title":"Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing","volume":"10","author":"Wei","year":"2014","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.mbs.2022.108954_b12","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI80142","article-title":"Ex vivo analysis identifies effective HIV-1 latency\u2013reversing drug combinations","volume":"125","author":"Laird","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.mbs.2022.108954_b13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/infdis\/jis412","article-title":"Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4+ T cells from infected individuals receiving effective antiretroviral therapy","volume":"206","author":"Blazkova","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"24","key":"10.1016\/j.mbs.2022.108954_b14","doi-asserted-by":"crossref","first-page":"14050","DOI":"10.1128\/JVI.01701-14","article-title":"Modeling the timing of antilatency drug administration during HIV treatment","volume":"88","author":"Petravic","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.mbs.2022.108954_b15","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3389\/fimmu.2017.00995","article-title":"Modeling kick-kill strategies toward HIV cure","volume":"8","author":"Hernandez-Vargas","year":"2017","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.mbs.2022.108954_b16","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s11538-019-00621-0","article-title":"Modeling HIV dynamics under combination therapy with inducers and antibodies","volume":"81","author":"Yan","year":"2019","journal-title":"Bull. Math. Biol."},{"issue":"20","key":"10.1016\/j.mbs.2022.108954_b17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123052","article-title":"Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design","volume":"3","author":"Ke","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.mbs.2022.108954_b18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11538-021-00875-7","article-title":"Modeling the effects of latency reversing drugs during HIV-1 and SIV brain infection with implications for the \u201cshock and kill\u201d strategy","volume":"83","author":"Roda","year":"2021","journal-title":"Bull. Math. Biol."},{"issue":"37","key":"10.1016\/j.mbs.2022.108954_b19","doi-asserted-by":"crossref","first-page":"13475","DOI":"10.1073\/pnas.1406663111","article-title":"Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1","volume":"111","author":"Hill","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.mbs.2022.108954_b20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005237","article-title":"Modeling the effects of vorinostat in vivo reveals both transient and delayed HIV transcriptional activation and minimal killing of latently infected cells","volume":"11","author":"Ke","year":"2015","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.mbs.2022.108954_b21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity"},{"issue":"23","key":"10.1016\/j.mbs.2022.108954_b22","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy","volume":"106","author":"Dinoso","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.mbs.2022.108954_b23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.tim.2015.11.003","article-title":"Reversal of latency as part of a cure for HIV-1","volume":"24","author":"Rasmussen","year":"2016","journal-title":"Trends Microbiol."},{"issue":"6091","key":"10.1016\/j.mbs.2022.108954_b24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1126\/science.1225416","article-title":"Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses","volume":"337","author":"Burton","year":"2012","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.mbs.2022.108954_b25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI80561","article-title":"Towards HIV-1 remission: potential roles for broadly neutralizing antibodies","volume":"126","author":"Halper-Stromberg","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.mbs.2022.108954_b26","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.mbs.2022.108954_b27","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.mbs.2022.108954_b28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/COH.0000000000000641","article-title":"Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission","volume":"15","author":"Gunst","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"7379","key":"10.1016\/j.mbs.2022.108954_b29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mbs.2022.108954_b30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-04160-3","article-title":"Anti-proliferative therapy for HIV cure: a compound interest approach","volume":"7","author":"Reeves","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mbs.2022.108954_b31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.aml.2019.02.019","article-title":"HIV low viral load persistence under treatment: Insights from a model of cell-to-cell viral transmission","volume":"94","author":"Wang","year":"2019","journal-title":"Appl. Math. Lett."},{"issue":"1","key":"10.1016\/j.mbs.2022.108954_b32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40840-018-0699-5","article-title":"Analysis of an HIV model with immune responses and cell-to-cell transmission","volume":"43","author":"Guo","year":"2020","journal-title":"Bull. Malays. Math. Sci. Soc."},{"issue":"10","key":"10.1016\/j.mbs.2022.108954_b33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000533","article-title":"Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy","volume":"5","author":"Rong","year":"2009","journal-title":"PLoS Comput. Biol."},{"issue":"8","key":"10.1016\/j.mbs.2022.108954_b34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat. Med."},{"issue":"7362","key":"10.1016\/j.mbs.2022.108954_b35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature10347","article-title":"Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy","volume":"477","author":"Sigal","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mbs.2022.108954_b36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13662-016-0952-x","article-title":"Viral dynamics of an HIV model with latent infection incorporating antiretroviral therapy","volume":"2016","author":"Wang","year":"2016","journal-title":"Adv. Differ. Equ."},{"issue":"6","key":"10.1016\/j.mbs.2022.108954_b37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00285-021-01604-3","article-title":"Dynamics of a new HIV model with the activation status of infected cells","volume":"82","author":"Guo","year":"2021","journal-title":"J. Math. Biol."},{"issue":"6","key":"10.1016\/j.mbs.2022.108954_b38","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s11538-007-9203-3","article-title":"Emergence of HIV-1 drug resistance during antiretroviral treatment","volume":"69","author":"Rong","year":"2007","journal-title":"Bull. Math. Biol."},{"issue":"1","key":"10.1016\/j.mbs.2022.108954_b39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0025-5564(93)90043-A","article-title":"Dynamics of HIV infection of CD4+ T cells","volume":"114","author":"Perelson","year":"1993","journal-title":"Math. Biosci."},{"issue":"17","key":"10.1016\/j.mbs.2022.108954_b40","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1073\/pnas.1419162112","article-title":"Post-treatment control of HIV infection","volume":"112","author":"Conway","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.mbs.2022.108954_b41","first-page":"3341","article-title":"Global analysis of within host virus models with cell-to-cell viral transmission","volume":"19","author":"Pourbashash","year":"2014","journal-title":"Discrete Contin. Dyn. Syst. Ser. B"},{"issue":"1","key":"10.1016\/j.mbs.2022.108954_b42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00285-020-01513-x","article-title":"Modeling the role of macrophages in HIV persistence during antiretroviral therapy","volume":"81","author":"Guo","year":"2020","journal-title":"J. Math. Biol."},{"key":"10.1016\/j.mbs.2022.108954_b43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtbi.2016.12.015","article-title":"Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy","volume":"416","author":"Wang","year":"2017","journal-title":"J. Theoret. Biol."},{"issue":"7","key":"10.1016\/j.mbs.2022.108954_b44","first-page":"3543","article-title":"Modeling within-host viral dynamics: The role of CTL immune responses in the evolution of drug resistance","volume":"26","author":"Deng","year":"2021","journal-title":"Discrete Contin. Dyn. Syst. Ser. B"},{"key":"10.1016\/j.mbs.2022.108954_b45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.matcom.2015.11.011","article-title":"Analysis of HIV models with multiple target cell populations and general nonlinear rates of viral infection and cell death","volume":"124","author":"Wang","year":"2016","journal-title":"Math. Comput. Simul."},{"key":"10.1016\/j.mbs.2022.108954_b46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.matcom.2017.07.006","article-title":"Modeling the role of acquired immune response and antiretroviral therapy in the dynamics of HIV infection","volume":"144","author":"Dubey","year":"2018","journal-title":"Math. Comput. Simul."},{"issue":"1","key":"10.1016\/j.mbs.2022.108954_b47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000600","article-title":"Broadly-neutralizing antibodies (bnabs) for the treatment and prevention of HIV infection","volume":"15","author":"Caskey","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1","key":"10.1016\/j.mbs.2022.108954_b48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mbs.2008.10.006","article-title":"Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips","volume":"217","author":"Rong","year":"2009","journal-title":"Math. Biosci."},{"issue":"1\u20132","key":"10.1016\/j.mbs.2022.108954_b49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-5564(02)00108-6","article-title":"Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission","volume":"180","author":"van\u00a0den Driessche","year":"2002","journal-title":"Math. Biosci."},{"issue":"2","key":"10.1016\/j.mbs.2022.108954_b50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2249.1992.tb03068.x","article-title":"Laboratory control values for CD4 and CD8 T lymphocytes. implications for HIV-1 diagnosis","volume":"88","author":"Bofill","year":"1992","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.mbs.2022.108954_b51","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1086\/368164","article-title":"Determining the relative efficacy of highly active antiretroviral therapy","volume":"187","author":"Louie","year":"2003","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.mbs.2022.108954_b52","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"issue":"8","key":"10.1016\/j.mbs.2022.108954_b53","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1172\/JCI92684","article-title":"Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency","volume":"127","author":"Archin","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.mbs.2022.108954_b54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.mbs.2022.108954_b55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bulm.2004.10.004","article-title":"Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects","volume":"67","author":"Smith","year":"2005","journal-title":"Bull. Math. Biol."},{"issue":"3","key":"10.1016\/j.mbs.2022.108954_b56","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10884-008-9111-8","article-title":"Threshold dynamics for compartmental epidemic models in periodic environments","volume":"20","author":"Wang","year":"2008","journal-title":"J. Dyn. Differ. Equ."},{"issue":"5","key":"10.1016\/j.mbs.2022.108954_b57","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s11538-013-9831-8","article-title":"Pulse HIV vaccination: feasibility for virus eradication and optimal vaccination schedule","volume":"75","author":"Yang","year":"2013","journal-title":"Bull. Math. Biol."},{"issue":"4","key":"10.1016\/j.mbs.2022.108954_b58","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00285-011-0474-9","article-title":"Threshold virus dynamics with impulsive antiretroviral drug effects","volume":"65","author":"Lou","year":"2012","journal-title":"J. Math. Biol."},{"key":"10.1016\/j.mbs.2022.108954_b59","series-title":"Dynamical Systems in Population Biology","author":"Zhao","year":"2003"},{"issue":"9","key":"10.1016\/j.mbs.2022.108954_b60","doi-asserted-by":"crossref","first-page":"e02092","DOI":"10.1128\/JVI.02092-16","article-title":"Relationship between measures of HIV reactivation and decline of the latent reservoir under latency-reversing agents","volume":"91","author":"Petravic","year":"2017","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.mbs.2022.108954_b61","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2796.2011.02457.x","article-title":"HIV reservoirs and the possibility of a cure for HIV infection","volume":"270","author":"Palmer","year":"2011","journal-title":"J. Inter. Med."},{"issue":"6","key":"10.1016\/j.mbs.2022.108954_b62","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/cid\/cit813","article-title":"A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1\u2013infected adults on antiretroviral therapy","volume":"58","author":"Spivak","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.mbs.2022.108954_b63","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11904-016-0299-7","article-title":"Broadly neutralizing antibodies for HIV eradication","volume":"13","author":"Stephenson","year":"2016","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"1316","key":"10.1016\/j.mbs.2022.108954_b64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1098\/rspb.1991.0136","article-title":"A mathematical model of vaccination against HIV to prevent the development of AIDS","volume":"246","author":"Nowak","year":"1991","journal-title":"Proc. R. Soc. Lond. [Biol]"},{"issue":"01","key":"10.1016\/j.mbs.2022.108954_b65","doi-asserted-by":"crossref","DOI":"10.1142\/S1793524516500054","article-title":"The effect of vaccination to dendritic cell and immune cell interaction in HIV disease progression","volume":"9","author":"Roy","year":"2016","journal-title":"Int. J. Biomath."},{"issue":"5","key":"10.1016\/j.mbs.2022.108954_b66","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/COH.0000000000000490","article-title":"Modeling HIV persistence and cure studies","volume":"13","author":"Hill","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.mbs.2022.108954_b67","first-page":"33","article-title":"Asymptotically autonomous epidemic models","volume":"1","author":"Castillo-Chavez","year":"1995","journal-title":"Math. Popul. Dyn. Anal. Heterog."},{"issue":"2","key":"10.1016\/j.mbs.2022.108954_b68","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1137\/0524026","article-title":"Persistence under relaxed point-dissipativity (with application to an endemic model)","volume":"24","author":"Thieme","year":"1993","journal-title":"SIAM J. Math. Anal."}],"container-title":["Mathematical Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556422001432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556422001432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:24:41Z","timestamp":1758417881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025556422001432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":68,"alternative-id":["S0025556422001432"],"URL":"https:\/\/doi.org\/10.1016\/j.mbs.2022.108954","relation":{},"ISSN":["0025-5564"],"issn-type":[{"value":"0025-5564","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards a new combination therapy with vectored immunoprophylaxis for HIV: Modeling \u201cshock and kill\u201d strategy","name":"articletitle","label":"Article Title"},{"value":"Mathematical Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mbs.2022.108954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108954"}}